These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34791812)

  • 1. Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
    Ishida M; Morimoto K; Yamada T; Shiotsu S; Chihara Y; Yamada T; Hiranuma O; Morimoto Y; Iwasaku M; Tokuda S; Takeda T; Takayama K
    Thorac Cancer; 2022 Jan; 13(2):173-181. PubMed ID: 34791812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
    Katayama Y; Yamada T; Sawada R; Kawachi H; Morimoto K; Watanabe S; Watanabe K; Takeda T; Chihara Y; Shiotsu S; Hibino M; Harada T; Nishioka N; Iwasaku M; Tokuda S; Takayama K
    Oncologist; 2024 May; 29(5):e681-e689. PubMed ID: 38241181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
    JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).
    Yamaguchi O; Mori K; Takata S; Shibata K; Chikamori K; Kimura N; Nagai Y; Nakagawa T; Igawa S; Harada T; Yoshioka H; Tanaka H; Nogawa H; Satoh H; Shiozawa T; Tsuji K; Kobayashi K; Kaira K
    Thorac Cancer; 2024 Jan; 15(2):163-171. PubMed ID: 38013668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
    Pérol M; Winfree KB; Cuyun Carter G; Lin Cui Z; Bowman L; Garon EB
    Lung Cancer; 2019 May; 131():6-13. PubMed ID: 31027699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients.
    Shiono A; Kaira K; Mouri A; Yamaguchi O; Hashimoto K; Uchida T; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
    Thorac Cancer; 2019 Apr; 10(4):775-781. PubMed ID: 30809973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
    Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
    Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
    Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
    Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).
    Hata A; Katakami N; Shimokawa M; Mitsudomi T; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2018 Nov; 19(6):e865-e869. PubMed ID: 30206044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
    Garon EB; Winfree KB; Molife C; Cui ZL; Arriola E; Levy B; Mekhail T; Pérol M
    Support Care Cancer; 2021 Jan; 29(1):117-125. PubMed ID: 32318871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
    Garon EB; Scagliotti GV; Gautschi O; Reck M; Thomas M; Iglesias Docampo L; Kalofonos H; Kim JH; Gans S; Brustugun OT; Orlov SV; Cuyun Carter G; Zimmermann AH; Oton AB; Alexandris E; Lee P; Wolff K; Stefaniak VJ; Socinski MA; Pérol M
    ESMO Open; 2020 Jan; 5(1):. PubMed ID: 31958290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
    Onoi K; Yamada T; Morimoto K; Kawachi H; Tsutsumi R; Takeda T; Okada A; Tamiya N; Chihara Y; Shiotsu S; Takemura Y; Yamada T; Hasegawa I; Katayama Y; Iwasaku M; Tokuda S; Takayama K
    Target Oncol; 2024 May; 19(3):411-421. PubMed ID: 38467958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer.
    Sakaguchi T; Furuya N; Ito K; Hida N; Morikawa K; Komase Y; Inoue T; Hataji O; Mineshita M
    Thorac Cancer; 2020 Jun; 11(6):1559-1565. PubMed ID: 32291896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.
    Furuya N; Ito K; Sakaguchi T; Hida N; Kakinuma K; Morikawa K; Inoue T; Komase Y; Hataji O; Mineshita M
    Oncology; 2020; 98(9):661-668. PubMed ID: 32464632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease.
    Igawa S; Yokoba M; Takakura A; Hosotani S; Nakahara Y; Sato T; Mitsufuji H; Sasaki J; Naoki K
    Invest New Drugs; 2022 Feb; 40(1):182-189. PubMed ID: 34415485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study).
    Nakamura A; Yamaguchi O; Mori K; Miura K; Tamiya M; Oba T; Yanagitani N; Mizutani H; Ninomiya T; Kajiwara T; Ito K; Miyanaga A; Arai D; Kodama H; Kobayashi K; Kaira K
    Eur J Cancer; 2023 May; 184():62-72. PubMed ID: 36905770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort study.
    Matsumoto K; Tamiya A; Inagaki Y; Taniguchi Y; Matsuda Y; Kawachi H; Tamiya M; Tanizaki S; Uchida J; Ueno K; Yanase T; Suzuki H; Atagi S
    J Geriatr Oncol; 2022 Mar; 13(2):207-213. PubMed ID: 34602370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Retrospective Analysis of the Efficacy of Oral Dexamethasone in Combination With Docetaxel Plus Ramucirumab Therapy for Previously Treated Lung Cancer.
    Hamai K; Katsura R; Miyake S; Fujita S; Tada S; Hirakawa T; Ueno S; Tanimoto T; Ishikawa N
    Cancer Control; 2024; 31():10732748241274615. PubMed ID: 39120923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study.
    Kasahara N; Sunaga N; Kuwako T; Naruse I; Imai H; Jingu A; Tsukagoshi Y; Masuda T; Kitahara S; Tsurumaki H; Yatomi M; Hara K; Koga Y; Sakurai R; Mori K; Kaira K; Maeno T; Asao T; Hisada T
    Support Care Cancer; 2020 Oct; 28(10):4825-4831. PubMed ID: 31982960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
    Tamura N; Horinouchi H; Sekine K; Matsumoto Y; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
    Thorac Cancer; 2019 May; 10(5):1141-1148. PubMed ID: 30913364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.